TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06495112

Intervention type: OTHER
Group type: OTHER
Intervention: Soft contact lens with lathe cut technique Lathe
Description: athe cut technique Lathe cutting involves shaping a solid block of lens material into the desired form using precision machinery. This method allows for customized lens designs but may result in a less smooth surface compared to cast molding. Cast molding, on the other hand, uses a liquid monomer that is cured in a mold to form the lens. This technique typically results in a smoother and more uniform lens surface.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Soft contact lens with cast molding technique
Description: Participants in this arm would receive Cast molding soft contact lenses and would wear them according to the study protocol, also likely for a specified duration.The cast molding technique for soft contact lenses involves creating lenses by polymerizing a liquid monomer mixture within a mold that forms the desired lens shape. Here's a brief overview of the steps involved in the cast molding process
Study: NCT06552156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Emulsifier
Description: Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.
Study: NCT06511739

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SYHX1901
Description: SYHX1901 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: SYHX1901 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: SYHX1901 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: SYHX1901 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral tablet
Study: NCT06395402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 dotatate therapy
Description: LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutetium Lu 177 dotatate therapy
Description: LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
Study: NCT06313931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cognitive training via immersive virtual reality
Description: 20 minutes per session, twice a week for six weeks (totaling 12 sessions), using the cupboard task application.
Study: NCT04937608

Intervention type: DIAGNOSTIC_TEST
Intervention: Sperm analysis
Description: Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sperm analysis
Description: Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
Study: NCT05606549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marital self disclosure
Description: Intervention time during hospitalization is the first day after chemotherapy, and intervene once per chemotherapy, a total of 4 times, 40-60 min each time. Interventions included verbal and written disclosure. The researcher will preside over the MSD process and introduce of MSD for gastric patients and their spouse，both patient and their spouse will receive a training or review on MSD skills, 5-10 minutes each time. Couples practice MSD skills through 4 revealing themes. Couples are encouraged to express their FCR, and when one partner disclosure, supporters should allow the speaker to fully express their feelings and respond positively to the speaker's message, showing empathy for them, and acknowledging their point of view.
Study: NCT06456229

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nestle Isocal
Description: Nestle Isocal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestle Boost Optimum
Description: Nestle Boost Optimum
Study: NCT05674981

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic group
Description: Two-strain probiotic supplement includes Lactobacillus reuteri ADR-1 (alive) and Lactobacillus rhamnosus GM-020 ( alive).
Study: NCT06313931

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training via paper and pencil
Description: 20 minutes per session, twice a week for six weeks (totaling 12 sessions), using cards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor stimulation
Description: motor stimulation for 12 sessions (20 minutes per session)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor stimulation
Description: motor stimulation for 12 sessions (20 minutes per session)
Study: NCT05882799

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided dry needling
Description: Ultrasound-guided dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle while monitoring the needle's progress with real-time ultrasound imaging. In this technique, a trained practitioner visualizes the piriformis muscle and the surrounding structures using an ultrasound machine, and then inserts the needle through the skin and into the muscle tissue, guided by the ultrasound image.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blinded dry needling
Description: Blinded dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle without using real-time imaging guidance. In this technique, the practitioner relies solely on their palpation skills to locate the trigger points of the piriformis muscle and inserts the needle through the skin and into the muscle tissue.
Study: NCT05674981

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
Study: NCT05127902

Intervention type: DIAGNOSTIC_TEST
Intervention: Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)
Description: Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG_max) for comparison with normalization signal processing program in Noraxon System.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)
Description: Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG_max) for comparison with normalization signal processing program in Noraxon System.
Study: NCT05379114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INVESTIGATIONAL DEVICE
Description: new medical device for the treatment of head lice infestation: Paranix ®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device
Description: well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
Study: NCT04863339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
Study: NCT05682781

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Description: Oral Nutritional Supplement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Dietary Counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Dietary Counseling
Study: NCT05200520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite Self-Regulation Intervention
Description: The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
Study: NCT04853979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRONE POSITION
Description: Any combination of prone or side position for 3 hours, 3 times a day for 3 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRONE POSITION
Description: Any combination of prone or side position for 3 hours, 3 times a day for 3 days
Study: NCT05633121

Intervention type: PROCEDURE
Intervention: Rheopheresis
Description: Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
Study: NCT05208294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulpiride 400 MG
Description: The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulpiride 400 MG
Description: The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive an inactive placebo capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive an inactive placebo capsule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High expectation manipulation
Description: Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High expectation manipulation
Description: Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low expectation manipulation
Description: Participants will be told by the study clinicians that an inactive placebo capsule is administrated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low expectation manipulation
Description: Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
Study: NCT03285087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEX 0.2 μg/kg/h.
Description: DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
Study: NCT05250050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study: NCT06552156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Emulsifier
Description: Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Emulsifier
Description: Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Emulsifier
Description: Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Emulsifier
Description: Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Emulsifier
Description: Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.
Study: NCT05250050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study: NCT06076460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Total Enteral Feeding
Description: This group will receive enteral feeding volumes at a rate of 80 ml/kg/day starting within the first two hours after birth. Volumes will increased by 20 ml/kg/day till day 4 (total 140 ml/kg/d) and then 150ml/kg/day on day 5.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Enteral Feeding
Description: This group will receive enteral feeding volumes at a rate of 20 ml/kg/day starting within the first two hours after birth and rest of the daily requirement as Total parenteral nutrition. Volumes will be increased by 20 ml/kg/day till day 3 and thereafter by 30 ml/kg/d till 150ml/kg/day on day 6.
Study: NCT05250050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g qid
Study: NCT06387550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: Warm up phase that include hip circles and shoulder rolls(1 sets of 5 reps), participants are trained on bicycle ergometer for 15 minutes on 2-3 times a week and its duration is increased according to patient tolerance, after that they will be pass through exercise phase that include squating, lunges and leg press (8-10 reps of 3 sets) after that cool down phase begin that include cat cow stretch and oblique stretch (5 reps of 1 set)
Study: NCT05250050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 0.5g qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 0.5g qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: 0.5g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: 0.5g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: 0.5g qid
Study: NCT05010941

Intervention type: DEVICE
Intervention: Hypotension Prediction Index
Description: Hypotension Prediction Index monitored via radial arterial line
Study: NCT05529979

Intervention type: DEVICE
Intervention: EPIONE® CT-Guided Percutaneous procedures
Description: The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
Study: NCT05623254

Intervention type: OTHER
Group type: OTHER
Intervention: no comparator - TAU (Treatment-as-usual)
Description: Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) \[Time Frame: At Three-six months\]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)
Study: NCT04699292

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: RADIATION
Intervention: Preoperative RT 36Gy
Description: Preoperative radiotherapy to 36Gy (equivalent)

Intervention type: RADIATION
Intervention: Preoperative RT 50Gy
Description: Preoperative radiotherapy to 50Gy (equivalent)

Intervention type: RADIATION
Intervention: Postoperative RT 50-66Gy
Description: Postoperative radiotherapy to 50-66Gy (equivalent)

Intervention type: RADIATION
Intervention: RT 36Gy
Description: Definitive radiotherapy to 36Gy (equivalent)
Study: NCT06276218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clavicular brace
Description: Clavicular brace for conservative treatment of closed midshaft clavicular fractures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clavicular brace
Description: Clavicular brace for conservative treatment of closed midshaft clavicular fractures
Study: NCT05518773

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT04691622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus -specific T-cell (NST) therapy
Description: Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.
Study: NCT06450860

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Interventions
Description: Individualized food provision and/or supplemental referral based on participant's unique needs/responses to assessment (NSAT). Food provision interventions include medically tailored meals, home delivered prepared meals, grocery boxes, grocery delivery services, food pantries, and soup kitchens/meal sites. Supplemental interventions include SNAP benefit enrollment support, nutrition education, and cooking education.
Study: NCT05110794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered Orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered Orally.
Study: NCT05862402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-adjustment by PKPD
Description: Dose-adjustment by pharmacokinetic and pharmacodynamic using Monte Carlo simulation